# CarePath Access Operations Demo

## Buyer Brief
- Product: CarePath AI
- Buyer: Patient access, care navigation, discharge, and population health leaders
- Agent: Scheduling Agent
- Status: executable-demo
- Executable route: /workflows/carepath-high-risk-followup-routing

## Objective
Demonstrate how a fragmented high-risk follow-up queue becomes a reviewable operational routing packet.

## Synthetic Scenario
A deterministic synthetic access packet is organized into routing rationale, missing evidence, escalation signals, reviewer ownership, and blocked unsafe actions.

## Guided Evaluation
- Inspect the synthetic workflow objective and execution steps.
- Review routing rationale, missing evidence, and human-review requirements.
- Inspect the deterministic result fixture and Watchtower trace.
- Confirm patient outreach and live routing remain blocked.

## Inspectable Proof
- [Workflow result](/workflows/results/carepath-high-risk-followup-routing): Deterministic output signals, review state, blocked actions, and Watchtower trace.
- [CarePath module](/modules/carepath-ai): Module scope, buyer value, and clinical safety boundary.
- [Synthetic validation](/synthetic/validation): Fixture-backed checks without production patient data.

## Inspectable Outcomes
- Structured access workqueue
- Routing and escalation rationale
- Reviewer ownership
- Blocked patient-facing actions

## Success Signals
- Access bottlenecks surfaced
- Manual review time targeted for reduction
- Escalation reasons made inspectable
- Trust trace retained

## Governance Boundaries
- Human review is required before any external action.
- Synthetic fixtures only.
- Every blocked action remains visible in the result packet.

## Production Exclusions
- No live patient routing
- No emergency triage replacement
- No autonomous outreach
- No diagnosis or treatment recommendation

## Product Boundary
SCRIMED demos and pilot programs are governed synthetic evaluations for enterprise buyers. They do not ingest live PHI, diagnose, treat, submit payer transactions, contact patients, mutate production records, or autonomously execute clinical care.

This brief supports enterprise evaluation and pilot scoping. It is not clinical advice, a production authorization, a certification claim, or evidence of autonomous clinical execution.